Spanish Series of Patients Treated With the Radionuclide Lutetium177

  • End date
    Dec 31, 2035
  • participants needed
  • sponsor
    Sociedad Española de Medicina Nuclear e Imagen Molecular
Updated on 9 July 2021


This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.


Patient data will be collected from medical records after obtaining consent and retrospectively.

Condition endocrine diseases, Islet Ce417ll Cancer, enteropathy, gastrointestinal tumors, bowel disease, neuroendocrine tumour, Bowel Dysfunction, Gastrointestinal Neoplasm, Gastric Cancer, gastrointestinal tumor, digestive diseases, Endocrine disorder, endocrinopathy, endocrine disorders, Gastropathy, Cancer/Tumors, Intestinal Cancer, Neoplasms by Histologic Type, Stomach Cancer, Neoplasms by Site, gastrointestinal disease, neuroendocrine tumors, pancreatic neoplasm, digestive disease, Intestinal Diseases, Cancer, Germ cell tumor, Neuroectodermal Tumor, Endocrine neoplasm, Pancreatic disorder, Cancer (Pediatric), Neoplasms, Nerve Tissue, Pancreatic Disorders, bowel disorders, diseases of the intestinal tract, digestive disorders, Neoplasm of unspecified nature of digestive system, gastrointestinal tract tumor, Neuroendocrine Tumor, Gastrointestinal Diseases and Disorders, GASTROINTESTINAL DISORDER, Neurectoderma, gastric tumor, endocrine neoplasia, digestive disorder, intestinal disease, Stomach Discomfort, gastrointestinal disorders, intestinal tumors, Digestive System Disease, Digestive System Neoplasms, Pancreatic Cancer, Neoplasms, Germ Cell Tumors, endocrine disease, gastric neoplasm, gastrointestinal diseases, Ewing's Family Tumors, digestive system tumor
Treatment Lutetium [177Lu] oxodotreotide/dotatate
Clinical Study IdentifierNCT04949282
SponsorSociedad Española de Medicina Nuclear e Imagen Molecular
Last Modified on9 July 2021


Yes No Not Sure

Inclusion Criteria

Written informed consent must be obtained prior to any data collection
Patients must be diagnosed with unresectable or metastatic, progressive, somatostatin receptor positive tumour
Aged 18 years

Exclusion Criteria

Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note